Flecainide (monotherapy)
Pre-clinicalRecruitingDevelopment Stage
Premature Ventricular Beats
Premature Ventricular Beats, Premature Ventricular Complexes, Premature Ventricular Contraction (PVC), Arrhythmia Ventricular, Ventricular Dysfunction, Left, Ventricular Dysfunction, Cardiomyopathies, Secondary, Cardiomyopathies
Apr 26, 2024 → Dec 1, 2027
About Flecainide (monotherapy)
Flecainide (monotherapy) is a pre-clinical stage product being developed by Brain Biotech for Premature Ventricular Beats. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06949748. Target conditions include Premature Ventricular Beats, Premature Ventricular Complexes, Premature Ventricular Contraction (PVC).
What happened to similar drugs?
1 of 4 similar drugs in Premature Ventricular Beats were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06949748 | Pre-clinical | Recruiting |
Competing Products
8 competing products in Premature Ventricular Beats
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| dapoxetine | Yuhan | Phase 1/2 | 32 |
| PSD502, contains a mixture of lidocaine and prilocaine + Placebo | Shionogi | Phase 2/3 | 38 |
| Placebo + Cisapride | Johnson & Johnson | Approved | 35 |
| SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate Injection | Jiangsu Hengrui Medicine | Phase 3 | 40 |
| ranolazine | Gilead Sciences | Phase 2 | 35 |
| IX-01 + Placebo | ICON plc. | Phase 2 | 32 |
| Tramadol Hydrochloride & Placebo | Bausch Health | Phase 3 | 26 |
| Tramadol Hydrochloride + Placebo | Bausch Health | Phase 3 | 26 |